Pancreatic cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• FGFR 1
• HSP90 0
• CTNNB1 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• NTRK 1
• RET 0

24 of 78+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Cyprus· EU contribution €1,500,000· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Austria· EU contribution €230,185· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €4,366,500· until Dec 2030· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €2,497,125· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

5 of 58 running projects, newest first. Listed amounts together: €177.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Withdrawn

  IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

  NCT06487377· Shanghai Pudong Hospital· Updated 2 Sept 2026

  “Study was stopped Sponsor discretion. No patients were dosed.”Registry text, quoted unchanged. Source

• Terminated

  TCR-T Cell Therapy on Advanced Solid Tumors

  NCT05438667· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Updated 1 Sept 2026

  “In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has resolved to close all IT centers and discontinue the clinical research project.”Registry text, quoted unchanged. Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· BeOne Medicines· Updated 8 Jul 2026

  “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

  NCT06704724· Pfizer· Updated 22 May 2026

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Updated 9 Apr 2026

  “Sponsor discontinued the trial”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

  NCT07026916· Genfleet Therapeutics (Shanghai) Inc.· Updated 17 Nov 2025

  “Adjustment of Product Development Strategy”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

  NCT06690281· National Cancer Institute (NCI)· Updated 11 Sept 2025

  “PI left NIH.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

  NCT05634525· M.D. Anderson Cancer Center· Updated 25 Jul 2025

  “No participants enrolled”Registry text, quoted unchanged. Source

• Withdrawn

  TCR1020-CD8 T Cells in KRAS-mutated Cancers

  NCT06707896· University of Pennsylvania· Updated 25 Jun 2025

  “Administrative decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Astellas Pharma Global Development, Inc.· Source

• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  NCT03190941· National Cancer Institute (NCI)· Source

• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

  NCT07522073· Incyte Corporation· Source

• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Astellas Pharma Inc· Source

• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Source

• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

  NCT07619521· National Cancer Institute (NCI)· Source

• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Incyte Corp.· Source

• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  NCT06218914· AstraZeneca· Source

• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  NCT07629960· Blueprint Medicines Corporation· Source

• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Amgen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 300
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Single-Cell RNA Sequencing-Integrated Fibroblast Markers and Candidate Drug-Target Associations in Pancreatic Ductal Adenocarcinoma.

  Hum Mutat, Nov 2026

• A triptolide-associated prognostic model for personalized treatment stratification in pancreatic ductal adenocarcinoma.

  Med Oncol, Nov 2026

• Transcriptomic profiling reveals autophagy-associated programs and prognostic biomarkers in anoikis-resistant pancreatic cancer cells.

  BMC Cancer, Oct 2026

• GlycoRNA-related cellular program scoring identifies Siglec- and myeloid-associated tumor microenvironments for glycoRNA validation.

  Front Immunol, Oct 2026

• Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

  J Cachexia Sarcopenia Muscle, Oct 2026

• Coordinated upregulation of Hippo, NF-κB and interferon pathway genes in pancreatic ductal adenocarcinoma: a retrospective tissue qRT-PCR profiling study with external tumour-versus-non-tumour validation, molecular subtype and survival analyses.

  BMC Gastroenterol, Sept 2026

• Baseline cellular state shapes the molecular impact of mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) alleles in reconstituted pancreatic cancer cells.

  Mol Omics, Sept 2026

• Patient-specific integration of RNA expression, methylation-derived replication-timing proxies, and histomorphology for pancreatic cancer subtyping.

  PLoS One, Sept 2026

• Transcriptomic Profiling of Adhesion GPCRs in Pancreatic Adenocarcinoma Identifies ADGRG7 and ADGRF1 as Novel Diagnostic Biomarkers and Therapeutic Targets.

  Anticancer Res, Sept 2026

• Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarcinoma.

  Immunobiology, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.